SAN DIEGO, Sept. 9, 2016 /PRNewswire/ -- Trovagene, Inc.
(NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA)
molecular diagnostics, today announced that its Chief Scientific
Officer, Mark Erlander, PhD, will
present at the 3rd Annual Precision Medicine Congress taking place
September 12-13, 2016 at London
Heathrow Marriott Hotel, London,
UK.
Dr. Erlander is scheduled to present on Monday, September 12, 2016 at 11:50 am BST. The presentation, titled
Clinical Utility for Detection and Monitoring Circulating Tumor
DNA (ctDNA) From Urine and Plasma, will focus on the value of
noninvasive liquid biopsy ctDNA testing as a viable alternative to
tissue biopsy.
Presentation Highlights:
- Proven clinical utility of Trovagene's Trovera noninvasive,
highly sensitive and quantitative test vs tissue biopsy to identify
driver mutations as well as resistance mutations in late-stage
solid tumor cancers
- Data on promising emerging applications of urine and blood
based liquid biopsy, including early response biomarkers for drug
efficacy and patient response to therapy, monitoring for disease
progression and early detection of cancer
About the 3rd Annual Precision Medicine Congress
The congress was designed for a variety of stakeholders from
drug and DX developers, payers, healthcare providers, academics to
technology solution providers and will bring together a community
of experts working in all areas of precision and personalized
medicine such as biomarkers, CDx, translational medicine, clinical
trials, genomics, NGS, bioinformatics and health economics.
It will provide the opportunity for attendees to take home cutting
edge strategies, case study examples and methods to allow them to
both implement and take the vital next steps in delivering
precision medicine. This will be achieved through a vibrant
exhibition room full of technology providers showcasing their
technologies and other solutions, expert led case study
presentations and interactive Q&A panel discussions.
About Trovagene, Inc.
Headquartered in San Diego,
California, Trovagene is leveraging its proprietary
Precision Cancer Monitoring® (PCM) technology for the detection and
monitoring of circulating tumor DNA (ctDNA) in urine. The Company's
technology detects and quantitates oncogene mutations in cancer
patients for improved disease management. Trovagene's PCM
technology is designed to provide important clinical information
beyond the current standard of care, and is protected by
significant intellectual property including multiple issued patents
and pending patent applications globally.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of words
such as "anticipate," "believe," "forecast," "estimated" and
"intend," or other similar terms or expressions that concern
Trovagene's expectations, strategy, plans or intentions. These
forward-looking statements are based on Trovagene's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties of
patent protection and litigation; clinical trials involve a lengthy
and expensive process with an uncertain outcome, and results of
earlier studies and trials may not be predictive of future trial
results; uncertainties of government or fourth party payer
reimbursement; limited sales and marketing efforts and dependence
upon fourth parties; and risks related to failure to obtain FDA
clearances or approvals and noncompliance with FDA regulations. As
with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that our
Precision Cancer Monitoring® platform will be utilized
by oncologists or prove to be commercially successful. Trovagene
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk
factors set forth in Trovagene's Form 10-K for the year ended
December 31, 2015 and its other
periodic reports filed with the Securities and Exchange
Commission.
Trovagene
Contacts
|
|
|
|
Beth
Anderson
|
|
Vicki
Kelemen
|
VP, Finance &
Administration
|
|
Sr. Director,
Marketing Communications
|
858-952-7593
|
|
858-952-7652
|
ir@trovagene.com
|
|
vkelemen@trovagene.com
|
Logo - http://photos.prnewswire.com/prnh/20160520/370471LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-3rd-annual-precision-medicine-congress-300325379.html
SOURCE Trovagene, Inc.